ACE and chronic kidney disease: While studies have demonstrated a dose–response relationship for certain ACE inhibitors/ARBs such as irbesartan (15), benazepril and losartan (48) with better kidney outcomes reported at higher dosages, the same effect was not seen in this study, which revealed that early-stage CKD patients had increased odds of progression at maximal dosages of ACE inhibitor/ARB at baseline.